SUMMARY OF PRODUCT CHARACTERISTICS

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Dexacortone 0.5 mg chewable tablets for dogs and cats

2. QUALITATIVE AND QUANTITATIVE COMPOSITION

1 tablet contains

Active substance:
Dexamethasone 0.5 mg

Excipient(s):
For the full list of excipients, see section 6.1.

3. PHARMACEUTICAL FORM

Chewable tablet.
Light brown with brown spots, round and convex flavoured 8 mm tablet with a cross-shaped break line on one side.
Tablets can be divided into 2 or 4 equal parts.

4. CLINICAL PARTICULARS

4.1 Target species

Dogs and cats.

4.2 Indications for use, specifying the target species

For the symptomatic treatment or as adjunct treatment of inflammatory and allergic conditions in dogs and cats.

4.3 Contraindications

Do not use in animals with viral or mycotic infections.
Do not use in animals with diabetes mellitus or hyperadrenocorticism.
Do not use in animals with osteoporosis.
Do not use in animals with cardiac or renal dysfunction.
Do not use in animals with corneal ulcers.
Do not use in animals with gastro-intestinal ulceration.
Do not use in animals with burns.
Do not use concomitantly with attenuated alive vaccine.
Do not use in the case of glaucoma.
Do not use during pregnancy (see section 4.7).
Do not use in cases of hypersensitivity to the active substance, to corticosteroids or to any of the excipients. See also section 4.8.

4.4 Special warnings for each target species

Corticoid administration is to induce an improvement in clinical signs rather than a cure. The treatment should be combined with treatment of the underlying disease and/or environmental control.

4.5 Special precautions for use

Special precautions for use in animals
In cases where it has been deemed necessary to administer the product in the presence of bacterial, parasitic or fungal infection, the underlying infection should be treated concomitantly with suitable antibacterial, antiparasitic or antifungal therapy. Because of the pharmacological properties of dexamethasone, special care should be taken when the veterinary medicinal product is used in animals with a weakened immune system. Corticoids such as dexamethasone, exacerbate proteinaceous catabolism. Consequently, the product should be used with caution in old or malnourished animals. Corticoids such as dexamethasone should be used with caution in patients with hypertension. Since glucocorticosteroids are known to slow growth, use in young animals (under 7 months of age) should be based on a benefit/risk assessment by the attending veterinarian. Pharmacologically-active dose levels may lead to atrophy of the adrenal cortex, resulting in adrenal insufficiency. This may become apparent particularly after withdrawal of corticosteroid treatment. The dosage should be reduced and withdrawn gradually to avoid precipitation of adrenal insufficiency. Avoid long-term use with oral corticosteroids whenever possible. Should long-term use be indicated, a corticosteroid with a shorter duration of action e.g. prednisolone is more appropriate. With prednisolone, alternate-day therapy can be utilised for longer-term use to minimise adrenal insufficiency. Due to the long duration of effect of dexamethasone alternate day therapy is not an adequate way to allow the hypothalamic-pituitary-adrenal axis to recover (see section 4.9). The tablets are flavoured. In order to avoid any accidental ingestion, store tablets out of reach of animals.

Special precautions to be taken by the person administering the veterinary medicinal product to animals
Dexamethasone may cause hypersensitivity (allergic) reactions. Skin contact with the product should be avoided, especially in people with known hypersensitivity to dexamethasone or any of the excipients (e.g. povidone or lactose). Wash hands after use. Seek medical advice in case of hypersensitivity reactions. This product may be harmful to children after accidental ingestion. Do not leave the product unattended. Return unused part-tablets to the blister pack and use them on the next administration. Keep the blister in the outer carton to prevent access by children. In case of accidental ingestion seek medical advice immediately and show the package leaflet or label to the physician.
Dexamethasone can cause harm to unborn children. Pregnant women should avoid exposure. Absorption through the skin is negligible but it is recommended to immediately wash hands after handling the tablets to avoid hand-to-mouth contact.

4.6 Adverse reactions (frequency and seriousness)

Anti-inflammatory corticosteroids, such as dexamethasone, are known to exert a wide range of side effects. Whilst single high doses are generally well tolerated, they may induce severe side-effects in long-term use. Long-term use should therefore be avoided. Should long-term use be indicated, a corticosteroid with a shorter duration of action e.g. prednisolone is more appropriate (see section 4.5).

The significant dose related cortisol suppression noticed during therapy is a result of effective doses suppressing the hypothalamic-pituitary-adrenal axis. Following cessation of treatment, signs of adrenal insufficiency extending to adrenocortical atrophy can arise and this may render the animal unable to deal adequately with stressful situations. Consideration should therefore be given to means of minimising problems of adrenal insufficiency following the withdrawal of treatment.

The significant increase in triglycerides noticed can be a part of possible iatrogenic hyperadrenocorticism (Cushing's disease) involving significant alteration of fat, carbohydrate, protein and mineral metabolism, e.g. redistribution of body fat, increase in body weight, muscle weakness and wastage and osteoporosis may result. Cortisol suppression and an increase in plasma triglycerides is a very common side-effect of medication with corticoids (more than 1 in 10 animals treated).

The increase of alkaline phosphatase by glucocorticoids could be related to enlargement of the liver (hepatomegaly) with increased serum hepatic enzymes. Other changes in blood biochemical and haematological parameters probably associated with the use of glucocorticosteroids were significant effects noticed on lactate dehydrogenase (decrease) and albumin (increase) and on eosinophils, lymphocytes (decrease) and segmented neutrophils (increase).

A decrease in aspartate transaminase is also noticed.

Systemically administered corticosteroids may cause polyuria, polydipsia and polyphagia, particularly during the early stages of therapy. Some corticosteroids may cause sodium and water retention and hypokalaemia in long-term use. Systemic corticosteroids have caused deposition of calcium in the skin (calcinosis cutis). Corticosteroid use may delay wound healing and the immunosuppressant actions may weaken resistance to or exacerbate existing infections. In the presence of viral infections, corticosteroids may worsen or hasten the progress of the disease.

Gastrointestinal ulceration has been reported in animals treated with corticosteroids and gastrointestinal ulceration may be exacerbated by steroids in animals given non-steroidal anti-inflammatory drugs and in animals with spinal cord trauma.

Other adverse reactions that may occur are: inhibition of longitudinal growth of bones, skin atrophy, diabetes mellitus, euphoria, pancreatitis, decrease in thyroid hormone synthesis, increase in parathyroid hormone synthesis.

See also section 4.7.

4.7 Use during pregnancy and lactation

Do not use in pregnant animals. Studies in laboratory animals have shown that administration during early pregnancy may cause foetal abnormalities. Administration during the later stages of pregnancy may cause abortion or early parturition.
Use during lactation only according to the benefit/risk assessment by the responsible veterinarian.

4.8 Interaction with other medicinal products and other forms of interaction

Phenytoin, barbiturates, ephedrine and rifampicin, may accelerate the metabolic clearance of corticosteroids resulting in decreased blood levels and reduced physiological effect. The concomitant use of this veterinary medicinal product with non-steroidal anti-inflammatory drugs may exacerbate gastrointestinal tract ulceration. Because corticosteroids can reduce the immunoreponse to vaccination, dexamethasone should not be used in combination with vaccines or within two weeks after vaccination. Administration of dexamethasone may induce hypokalaemia and hence increase the risk of toxicity from cardiac glycosides. The risk of hypokalaemia may be increased if dexamethasone is administered together with potassium depleting diuretics.

4.9 Amounts to be administered and administration route

For oral administration. Dose: 0.05-0.2 mg/kg/day. The dose and duration of treatment should be determined by the veterinarian based upon the desired effect (anti-inflammatory or anti-allergic) and on the nature and severity of each individual case. The lowest effective dose for the shortest possible period should be used. When the desired effect has been achieved, the dose should gradually be reduced until the lowest effective dose is reached. Dogs should be treated in the morning and cats in the evening on account of differences in cortisol circadian rhythms.

Tablets can be divided into 2 or 4 equal parts to ensure accurate dosing. Place the tablet on a flat surface, with its scored side facing up and the convex (rounded) side facing the surface.

2 equal parts: press down with your thumbs on both sides of the tablet.
4 equal parts: press down with your thumb in the middle of the tablet.

4.10 Overdose (symptoms, emergency procedures, antidotes), if necessary

An overdose does not cause other adverse effects than those stated in section 4.6.
4.11 Withdrawal period(s)

Not applicable

5. PHARMACOLOGICAL PROPERTIES

Pharmacotherapeutic group: corticosteroids for systemic use, plain, glucocorticoids, dexamethasone.
ATCvet code: QH02AB02

5.1 Pharmacodynamic properties

Dexamethasone is a long-acting glucocorticosteroid; its potency is about 25 times greater than the short-acting substances, such as hydrocortisone. Glucocorticoids play a role in carbohydrate-, protein- and fat metabolism, and have an antiphlogistic and immunosuppressive effect. The main effect of glucocorticosteroids is the ability of these products to suppress inflammatory reactions, independent of the cause of the inflammation (infectious, allergic, chemical, mechanical). Thanks to the ability to inhibit phospholipase enzymes in the cell membranes, the formation of prostaglandins and leukotrienes is prevented.

5.2 Pharmacokinetic particulars

Following oral administration dexamethasone is well absorbed in dogs and cats. In plasma, dexamethasone is present in free form and bound to plasma proteins. In the liver, corticosteroids like dexamethasone are metabolised (glucuronidated and sulfated), therefore only a small amount of the active substance can be traced in the urine.

6. PHARMACEUTICAL PARTICULARS

6.1 List of excipients

Lactose monohydrate
Potato starch
Povidone K30
Magnesium stearate
Chicken Flavour
Yeast (dried)

6.2 Major incompatibilities

Not applicable

6.3 Shelf life

Shelf life of the veterinary medicinal product as packaged for sale: 2 years
Shelf life of the divided tablets: 6 days
6.4 Special precautions for storage

Return unused part-tablets to the blister pack and use them on the next administration. Do not store above 30ºC. Store in the original package in order to protect from light.

6.5 Nature and composition of immediate packaging

Aluminium - PVC/PE/PVDC blister. Cardboard box of 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 blisters of 10 tablets.
Not all pack sizes may be marketed.

6.6 Special precautions for the disposal of unused veterinary medicinal product or waste materials derived from the use of such products

Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal products should be disposed of in accordance with local requirements.

7. MARKETING AUTHORISATION HOLDER

Le Vet Beheer B.V.
Wilgenweg 7
3421 TV Oudewater
The Netherlands

8. MARKETING AUTHORISATION NUMBER

Vm 41821/5021

9. DATE OF FIRST AUTHORISATION

23 January 2018

10. DATE OF REVISION OF THE TEXT

July 2022

Approved 19 July 2022